The data leak on a melanoma vaccine undermined the lofty expectations set by Wall Street earlier this year.
New York | Moderna and Merck shares plummeted after data on the companies’ widely anticipated personalised melanoma vaccine wasn’t enough to prove to investors that a new era of cancer treatments has arrived.
The companies had initially announced in August that the bespoke vaccine led to a significant and clinically meaningful reduction in the recurrence of deadly tumours, sending shares of both companies soaring.
Gift articles to anyone you choose each month when you subscribe.
Compare how 6 other independent news outlets reported on this story.
The biotech company now expects 2026 revenue growth of 15% to 25%, up from its previous guidance of up to 10%.
Researchers have been chasing the dream of a cancer vaccine for decades. Some recent successes with mRNA technology are garnering excitement from patients, doctors, government and investors.
One in two women will experience a UTI in their lifetime – with one in four developing a chronic infection. Australian researchers are hoping to change this.
Men aged 50–69 and at average risk should get PSA screening every two years.
Paris-based Orakl Oncology has raised a $34M Series A to predict how cancer drugs will perform, using lab-grown copies of patients' tumours and AI.
One of the leading cancer organizations in the United States is raising the alarm over prostate cancer and directly urging men to get screened.
